Bli medlem
Bli medlem

Du är här

2015-04-08

Biofrontera AG: Biofrontera stabilizes shareholder structure

Biofrontera AG / Biofrontera stabilizes shareholder structure. Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
* Block trade completed off-market
* Biofrontera enters essential growth phase with long-term investors

Leverkusen, 08 April 2015 - Biofrontera AG (AIM/FSE: B8F), the
biopharmaceutical company focusing on skin cancer, has stabilized its
shareholder structure through an off market block trade of shares. Following
intensive selling over the stock markets, the one million remaining shares
owned by Dr. Carsten Maschmeyer, through his investment funds, were acquired
by existing institutional investors in Biofrontera.

"Biofrontera is in an important growth phase. Developments in 2015 will be
core to our future success, in particular with the preparations for the
market entry of Ameluz in the USA. In addition, we will progress the
indication expansion for basal cell carcinoma in Europe as quickly as
possible. In this phase we are delighted by the confidence of investors
taking up a block of shares on short notice, signalling their support for the
Company's strategy." said Biofrontera's CEO, Prof. Hermann Lübbert.

The shareholder structure of Biofrontera AG is published and regularly updated
on Biofrontera's homepage within the relevant reports.

Ends

Enquiries, please contact:

-----------------------------------------------------------------------
| Biofrontera AG +49 (0) 214 87 63 2 0 |
| |
|Prof. Hermann Lübbert, Chief Executive Officer press@biofrontera.com |
|Thomas Schaffer, Chief Financial Officer |
| www.biofrontera.com |
| IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514 |
| |
|Jürgen Benker |
| Nomad and Broker: Shore Capital +44(0) 20 7408 4090 |
| |
|Bidhi Bhoma / Toby Gibbs |
| IR UK: Seton Services +44(0) 20 7603 6797 |
| |
|Toni Vallen |
| Financial PR: Gable Communications +44(0) 20 7193 7463 |
| |
|John Bick +44 (0)7872 061007 |
-----------------------------------------------------------------------
Background:

TheBiofrontera Group
(FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product
isAmeluz®
, a prescription drug which is approved in Europe for the treatment of mild
and moderate actinic keratosis (superficial skin cancer) with photodynamic
therapy (light therapy). Biofrontera is the first German pharmaceutical
start-up company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz®to be approved for basal cell
carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United
States.

The company also markets the Belixos®dermatological range of cosmetics.
Belixos®products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the
moment, Belixos®cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These
forward-looking statements reflect the opinion of Biofrontera at the time of
this communication and involve certain known and unknown risks. The actual
results achieved by Biofrontera may differ significantly from future results
or performances which are published in its forward-looking statements.
Biofrontera assumes no responsibility to update its forward-looking
statements.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1909285

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.